Lisuride - axxonis

Drug Profile

Lisuride - axxonis

Alternative Names: Lisuride - subcutaneous; Lisuride - transdermal; Lisuride maleate; Lisuride Sub Q; Lisuride TDS; Lysuride; Nenad

Latest Information Update: 19 Apr 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer Schering Pharma
  • Developer axxonis Pharma
  • Class Antimigraines; Antiparkinsonians; Ergolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists; Serotonin 2B receptor antagonists; Serotonin 2C receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Restless legs syndrome
  • No development reported Parkinson's disease

Most Recent Events

  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
  • 18 Feb 2010 Lisuride is still in preregistration stage for Parkinson's disease in Switzerland
  • 07 Jan 2010 Suspended - Preregistration for Restless legs syndrome in European Union (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top